共 50 条
Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials
被引:49
|作者:
Cohen, Stephanie C.
[1
]
Mulqueen, Jilian M.
[2
]
Ferracioli-Oda, Eduardo
[3
]
Stuckelman, Zachary D.
[2
]
Coughlin, Catherine G.
[2
]
Leckman, James F.
[2
,4
]
Bloch, Michael H.
[2
,4
]
机构:
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA
[3] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil
[4] Yale Univ, New Haven, CT 06520 USA
基金:
美国国家卫生研究院;
关键词:
tics;
psychostimulants;
methylphenidate;
amphetamine;
meta-analysis;
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;
DEFICIT HYPERACTIVITY DISORDER;
LA-TOURETTES DISEASE;
ONCE-A-DAY;
DOUBLE-BLIND;
PHARMACOLOGICAL-TREATMENT;
RELEASE METHYLPHENIDATE;
STEREOTYPED BEHAVIOR;
OROS METHYLPHENIDATE;
STIMULANT TREATMENT;
D O I:
10.1016/j.jaac.2015.06.011
中图分类号:
B844 [发展心理学(人类心理学)];
学科分类号:
040202 ;
摘要:
Objective: Clinical practice currently restricts the use of psychostimulant medications in children with tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment. Our goal was to conduct a meta-analysis to examine the risk of new onset or worsening of tics as an adverse event of psychostimulants in randomized, placebo-controlled trials. Method: We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of psychostimulant medications in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). We used a fixed effects meta-analysis with risk ratio of new onset or worsening tics in children treated with psychostimulants compared to placebo. We used stratified subgroup analysis and meta-egression to examine the effects of stimulant type, dose, duration of treatment, recorder of side effect data, trial design, and mean age of participants on the measured risk of tics. Results: We identified 22 studies involving 2,385 children with ADHD for inclusion in our meta-analysis. New onset tics or worsening of tic symptoms were commonly reported in the psychostimulant (event rate = 5.7%, 95% CI = 3.7%-8.6%) and placebo groups (event rate = 6.5%, 95% CI = 4.4%-9.5%). The risk of new onset or worsening of tics associated with psychostimulant treatment was similar to that observed with placebo (risk ratio = 0.99, 95% CI = 0.78-1.27, z = 0.05, p = .962). Type of psychostirnulant, dose, duration of treatment, recorder, and participant age did not affect risk of new onset or worsening of tics. Crossover studies were associated with a significantly greater measured risk of tics with psychostimulant use compared to parallel group trials. Conclusion: Meta-analysis of controlled trials does not support an association between new onset or worsening of tics and psychostimulant use. Clinicians may want to consider rechallenging children who report new onset or worsening of tics with psychostimulant use, as these symptoms are much more likely to be coincidental rather than caused by psychostimulants.
引用
收藏
页码:728 / 736
页数:9
相关论文